Clinical Trial Update: SBRT in Multi-metastatic NSCLC Patients Which Are Pan-negative for Driver Mutations [Phase 2]

View source ↗

Summary

A Phase 2 trial is evaluating stereotactic body radiotherapy in multi-metastatic non-small cell lung cancer patients who are pan-negative for driver mutations, …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Leukine (sargramostim)

Snippet

Sponsor: Shanghai Chest Hospital | Conditions: NSCLC, SBRT | Phase 2 | Status: UNKNOWN